Bupranolol is a non-selective beta-blocker primarily indicated for the treatment of hypertension and tachycardia by inhibiting sympathetic stimulation to the heart. As a pharmaceutical agent, the accurate… Read more
Bupranolol is a non-selective beta-blocker primarily indicated for the treatment of hypertension and tachycardia by inhibiting sympathetic stimulation to the heart. As a pharmaceutical agent, the accurate characterization of this drug requires high-quality analytical support. This category provides access to essential reference standards, including the parent drug API, pharmacopeial and non-pharmacopeial impurities, and metabolites necessary for comprehensive impurity profiling. Additionally, stable isotope labelled compounds such as Bupranolol-d9 serve as critical internal standards in liquid chromatography-mass spectrometry (LC-MS) assays. These materials are utilized by pharmaceutical laboratories for rigorous method validation, the development of stability-indicating assays, and precise quantitative analysis during the quality control of formulations containing this active ingredient.